SEC Filing Analysis: Natera, Inc. (NTRA)

Executive Summary

• Trading Significance: Medium
• Key Takeaway: Executive Chairman Matthew Rabinowitz executed scheduled Rule 10b5-1 sales totaling 102,000 shares ($34.80M) while retaining over 2.12M direct shares.
• Market Impact: Neutral; transactions were structured across multiple price tiers under pre-established trading plans.

Company Information

Field	Value
Company	Natera, Inc.
Ticker Symbol	NTRA
CIK	0001604821
Industry	Services - Medical Laboratories

Insider Information

Field	Value
Name	Rabinowitz Matthew
CIK	0001646382
Title/Position	EXECUTIVE CHAIRMAN
Relationship	Director, Officer

Transaction Details

Field	Value
Form Type	4
Transaction Date	2026-09-14
Transaction Code	S (Open Market Sale)
Security Type	Common Stock
Shares Involved	102,000
Price Per Share	$341.15 (Weighted Average)
Total Value	$34,797,270.87
Shares Owned After	2,125,394 (Direct)
Ownership Type	Direct & Indirect

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$34,797,270.87
% of Market Cap	0.07%
Shares Transacted	102,000
% of Shares Outstanding	0.07%
Post-Transaction Ownership	2,125,394 shares (1.48% of outstanding)
Materiality Assessment	Low to Moderate (Routine Scheduled Plan)

Impact Evaluation

• Market Cap Context: In the context of Natera's $49.27 billion market capitalization, the $34.80M divestment represents a negligible 0.07% of market value.
• Ownership Concentration: Insider ownership remains high, with Rabinowitz continuing to hold 1.48% of total outstanding shares directly (valued at over $720M).
• Dilution Impact: None; transactions were open-market dispositions of existing shares.
• Transaction Significance: The disposition represents approximately 4.58% of the insider's total equity holdings, reflecting routine portfolio diversification rather than a shift in corporate confidence.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: Sales were executed pursuant to Rule 10b5-1 trading plans established well in advance (June 12, 2026 and December 5, 2025).

Volume & Sentiment

• Expected Volume Impact: Minimal; the sales were executed across numerous weighted-average price tranches across two consecutive trading days.
• Sentiment Indicator: Neutral

Additional Context

Transaction Notes

• Timing: Executed across September 14, 2026, and September 15, 2026.
• Special Circumstances: Conducted under pre-arranged Rule 10b5-1 plans. Includes 100,000 direct shares sold and 2,000 indirect shares sold by spouse.